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Previewsthe CLEC-2-mediated platelet activation.
Nagae et al. (2014) also determined the
crystal structure of the CLEC-2/rhodocy-
tin complex (Figure 1D). Interestingly, the
binding site of rhodocytin, a purely pro-
tein-protein interaction, on CLEC-2 over-
laps with that of podoplanin and utilizes
the conserved ‘‘Glu-Asp’’ motif. This
shows that the site for binding both
endogeonous and exogenous ligands is
conserved, suggesting a possibility that
the most advanced venomous snakes
have evolved toxins to target the binding
sites of conserved physiological ligands
as an effective strategy to capture and
digest the prey and prevail over the natu-
ral enemies.
CLRs often exist as dimers, which are
believed to be important for effective
signaling. For instance, some CLRs,
such as NKG2s, KACL, and Ly49s, utilize
a2 and b1’ site for dimerization and
recognize the ligands using the con-
ventional Ca2+-mediated sugar binding
site without the Ca2+ ion. However,
as mentioned, the classical region
corresponding to the Ca2+-mediated
sugar binding site of CLEC-2 is not
involved in ligand binding; rather, it is
diverted to mediating the dimerization.
Subsequently, in the context of this
unique dimer architecture, the ligand
binding site of CLEC-2 is exposed to
the cell surface and faces outward,1696 Structure 22, December 2, 2014 ª2014where it can be easily accessed by the
ligands.
As described above, the CLEC-2-
podoplanin interaction leads to platelet
aggregation and is involved in tumor
metastasis. Kato et al. recently esta-
blished novel antibodies for aberrantly
glycosylated podoplanin, which is
specifically expressed on tumor cells
(Kato and Kaneko, 2014). These anti-
bodies represent an advancement over
the well-characterized NZ-1 antibody,
which, although it can block the CLEC-
2-podoplanin interaction, also binds
to normal podoplanin-expressing cells.
Thus, such anti-podoplanin antibodies
that block the CLEC-2-podoplanin bind-
ing might be candidates for targeted
drug development to suppress tumor
metastasis. On the other hand, it is also
interesting to compare how CLEC-2
and antibodies recognize O-glycosylated
peptides and map out a detailed under-
standing of differences and similarities
between them.
Finally, the new face of the C-type lec-
tin-like domain of CLEC-2 for ligand bind-
ing clearly opens the possibility that CLRs
can utilize all surfaces as potential sites
for unidentified endogenous and exoge-
nous ligands, including those produced
by microorganisms, and employ different
dimer conformations in order to adjust
effective signaling.Elsevier Ltd All rights reservedACKNOWLEDGMENTS
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With a major leap in a long running saga, Jilkova and colleagues, in this issue of Structure, provide structural
and biochemical evidence for a role of sulfated polysaccharides in the activation of parasite digestive
proteases.Schistosomiasis (also known as bilharzia)
caused by parasitic worms of the genus
Schistosoma is endemic in over 70tropical/subtropical countries and infects
more than 200 million people, killing be-
tween 20,000 and 280,000 per annum(Lustigman et al., 2012). The infective
stage of Schistosoma mansoni, the most
common human schistosome, penetrates
Structure
Previewsthe skin of the host and makes its way
via the blood capillaries to the lungs
and subsequently to the mesenteric
blood vessels, where male and female
worms pair up and mate for many years.
The parasites are obligate blood feeders;
hence, they are termed blood flukes.
Blood proteins, particularly haemoglobin,
are an essential source of nutrients,
and the female worms, in particular,
exploit these to produce and release
numerous eggs. Eggs induce the exces-
sive immunopathology associated with
schistosomiasis when they get trapped
in host tissues, especially the liver.
Ever since Timms and Bueding (1959)
described the presence of proteases
in schistosome extracts and suggested
that they could be responsible for degrad-
ing haemoglobin to free amino acids in the
schistosome gut, we have been trying
to unravel the process. Today, we know
that papain-like (clan CA, family C1) pro-
teases, including cathepsins B1, L1, L3,
F, C, and an aspartic protease, cathepsin
D (clan AA) (Dalton et al., 2009; Dvora´k
et al., 2009), are produced in the parasite
gut. These enzymes may work in concert
or in some specific order that is regulated
by the pH of the gut, the pH optimum for
activity of each enzyme, and their sub-
strate specificity (Delcroix et al., 2006).
Importantly, schistosome parasites do
not possess an anus, and, hence, diges-
tion is performed in a bifurcated sac-like
gut from which the contents are regurgi-
tated regularly. Regardless of the position
each protease plays in the digestive pro-
cess, all are considered prime targets at
which we could develop novel antischis-
tosome drugs or vaccines (El Ridi et al.,
2014).
The pH of the parasite gut is in the range
of 4.0 to 6.5 (Delcroix et al., 2006) and is
not only considered important in regu-
lating the digestive function of the pro-
teases, but also their activation from
inactive precursors or ‘‘zymogens’’ that
are likely synthesized and secreted into
the gut lumen by the surrounding gastro-
dermal cells. A number of reports have
shown that both parasite and mammalian
cysteine proteases can be autocatalyti-
cally activated in vitro from zymogen to
mature enzyme by reducing the pH of
the solution (Dalton et al., 2009). The
schistosome cathepsin B1 (SmCB1) pro-
tease is rather unique in this respect, as
the zymogen does not autocatalyticallyactivate at low pH in vitro (Dalton et al.,
2009; Sajid et al., 2003). Within the para-
site gut, however, a mechanism for acti-
vating the SmCB1 zymogen was discov-
ered when it was shown that it (and the
other schistosome digestive enzymes)
possesses a cleavage site at the juncture
between the propeptide and mature
enzyme domains specific for the trans-
activating enzyme asparaginyl endopepti-
dase (SmAE) that is also found in the para-
site gut (Sajid et al., 2003; Dalton et al.,
1995). But then, it was demonstrated us-
ing RNA interference methods that, even
in the absence of detectable SmAE pro-
tein, SmCB1 is fully processed and active,
indicating that SmAE is not essential to
activate SmCB1 in vivo (Krautz-Peterson
and Skelly, 2008). So what is driving the
activation of SmCB1 within the schisto-
some gut?
In this issue of Structure, Jı´lkova´ et al.
(2014) have obtained crystallographic
structures of the zymogen, the mature
enzyme, and an inactive intermediate
form of SmCB1 and may have solved
the conundrum by discovering a fasci-
nating activation trigger that is mediated
by sulfate polysaccharides. This activa-
tion mode was originally reported for hu-
man procathepsin L (Mason and Massey,
1992) and Fasciola hepatica (Law et al.,
2003) when autoactivation of cathepsin
Bs was achieved by incubation with
dextran sulfate. What is interesting is
that the propeptide of the SmCB1 con-
tains a unique a helix, a-3p. This short he-
lix, residues 50 to 62, protrudes outside
the enzyme core and lies upstream of
the propeptide-mature enzyme juncture
and the SmAE cleavage site (Asn69-
Val70). It contains a heparin-binding
motif 55-LRRTRRP-61, which makes
little contact with the enzyme (except
for two hydrogen bonds formed by
Arg56 and Arg60) and is internally stabi-
lized by hydrogen bonds between the sol-
vent-exposed Arg57 and Arg59 and the
nearby resides, Arg57-Arp54-Arg-59-
Glu51-Arg60. This arrangement makes
a-3p an ideal point of interaction for
sulfated polysaccharides like dextran sul-
fate and heparin sulfate.
At low pH, the 37 kDa SmCB1 zymogen
autocatalytically produces an inactive in-
termediate of 32 kDa by clipping off 38
residues of the propeptide, but this does
not fully expose the active site. Adding
dextran sulfate to the mix facilitates theStructure 22, December 2, 2014nibbling away of a few more residues in
the vicinity of Met46, Gly47, Ala48, and
Ag49, which sit in the S1’, S1, S2, and S3
subsites of the active site, respectively,
to produce anactive 30–31kDa intermedi-
ate. This subsequently leads to process-
ing of SmCB1 to the full 28 kDa mature
enzyme by cleavage at Asn69-Val70,
which is identical to the cleavage site to
SmAE. Substitutions within the 55-
LRRTRRP-61 heparin-binding motif that
destabilizes its structure prevents this
neat dextran sulfate-mediated activation
process while still allowing the formation
of the inactive intermediate. Thus, binding
of sulfated polysaccharides to an intact
a-3p heparin-binding motif is required for
complete processing of the SmCB1.
Intriguingly, while sulfated polysaccha-
rides induced autocatalytic activation of
SmCB1, they had a negative effect on the
trans-activation of SmCB1 by SmAE
(without having a direct effect on SmAE it-
self). This persuaded the authors to pro-
pose that sulfated polysaccharides act as
a switch between the two activationmech-
anisms. We now have an alternative route
to SmCB1 activation via sulfated polysac-
charides, but the conservation of the
SmAE cleavage site within all the major
digestive proteases still suggests that this
is a major mechanism of activation.
Perhaps the gastrodermis is lined with
sulfatedglycoaminoglyansand/or imbibed
host tissues carry these into the gut and
activate the enzyme. Although it has yet
to be determined, other gut proteases,
suchasSmCL1,SmCF,andSmCL3, could
also behave as trans-activators of SmCB1
in the presence or absence of sulfated
polysaccharides. Schistosomes are very
clever worms and undoubtedly have
many routes and slip-roads to reach the
same destination, but, the more we learn
about these, the better we can shut them
off with new drugs or vaccines.REFERENCES
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